BlackRock Fund Advisors recently announced the acquisition of new stake in Cytosorbents Corporation (NASDAQ:CTSO). The institutional investor has increased its shareholding in the Healthcare company by 1.37% to 1.91 million shares with purchase of 25830.0 shares. This fresh investment now brings its stake to 5.27% valued currently at $19.51 million. In addition, The Vanguard Group, Inc. raised its holdings by 3612.0 to 1.35 million shares. And Skylands Capital LLC has lifted its position by 38.05% or 0.31 million shares – to 1.13 million shares.
With over 0.5 million Cytosorbents Corporation (CTSO) shares trading Thursday and a closing price of $9.96 on the day, the dollar volume was approximately $5.03 million. The shares have shown a positive weekly performance of 1.63% and its price on 07/02/20 lost nearly -0.10%. Currently, there are 33.98M common shares owned by the public and among those 32.62M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for CTSO have a consensus price objective of $13.58. The analysts have set the share’s price value over the next 12 months at a high of $17.00 and a low of $8.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Cytosorbents Corporation stock is 2.00 for the next 12 months. The average price target is 31.69% above its last price level and an upside to the estimated low will see the stock lose -24.5% over that period. But an upside of 41.41% will see the stock hit the forecast high price target while mean target price for the stock is $14.50.
Insiders at the company have transacted a total of 23 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 21 of these insider trades were purchases, accounting for 624,900 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 14,677 shares.
The top 3 mutual fund holders in Cytosorbents Corporation are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.77 million shares of the company’s stock, all valued at over $7.83 million. The company has a total holdings of about 2.12% of the shares outstanding. iShares Russell 2000 ETF bought 6625.0 shares to see its total holdings expand to 0.66 million shares valued at over $6.76 million and representing 1.83% of the shares outstanding. Vanguard Extended Market Index Fu bought 9049.0 shares to bring its total holdings to over 0.43 million shares at a value of $4.43 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.20% of the shares outstanding.
Shares of Cytosorbents Corporation (NASDAQ: CTSO) opened at $10.02, up $0.05 from a prior closing price of $9.97. However, the script later closed the day at $9.96, down -0.10%. The company’s stock has a 5-day price change of 1.63% and 30.20% over the past three months. CTSO shares are trading 158.70% year to date (YTD), with the 12-month market performance up to 52.76% higher. It has a 12-month low price of $3.49 and touched a high of $11.24 over the same period. Currently, 0.5 million shares have been traded, compared to an average intraday trading volume of 765.71K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.46%, 2.75%, and 61.44% respectively.
Institutional ownership of Cytosorbents Corporation (NASDAQ: CTSO) shares accounts for 27.90% of the company’s 33.98M shares outstanding. Mutual fund holders own 15.84%, while other institutional holders and individual stakeholders account for 20.93% and 11.71% respectively.
It has a market capitalization of $361.25M and a beta (3y monthly) value of 0.56. The stock’s earnings-per-share (ttm) stands at -$0.55. The company has a Quick Ratio of 3.10 with the debt-to-equity ratio at 0.71. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.61% over the week and 6.84% over the month.
Analysts forecast that Cytosorbents Corporation (CTSO) will achieve an EPS of -$0.08 for the current quarter, -$0.1 for the next quarter and -$0.15 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.11 while analysts give the company a high EPS estimate of -$0.05. Comparatively, EPS for the current quarter was -$0.11 a year ago. Earnings per share for the fiscal year are expected to decrease by -6.60%, and 60.50% over the next financial year. EPS over the next five years should compared to 14.30% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Cytosorbents Corporation (CTSO) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the CTSO, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on August 08, 2017, with the firm’s price target at $10-$12. Aegis Capital coverage for the Cytosorbents Corporation (CTSO) stock in a research note released on October 26, 2016 offered a Buy rating with a price target of . Maxim Group was of a view on May 24, 2016 that the stock is Buy, while WBB Securities gave the stock Buy rating on October 29, 2015, issuing a price target of $13- $13. MLV & Co on their part issued Buy rating on May 12, 2015.